Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Healthy Skin Books

Kaal is a proud Noongar boy, he loves playing football, but this season Kaal is about to tackle a new and unexpected challenge… eczema.

Research

Molecular Detection of Scabies by PCR Using a Next Generation Sequencing (NGS) Approach

In recent years, the interest in molecular diagnostic methods for the detection of many pathogens has grown substantially.

Research

Moorditj Marp (Strong Skin) Evaluation and development of culturally relevant healthy skin storybooks

Co-designed and in collaboration with community members, the impacts of this project will directly benefit families by building awareness, empowering decision-making, and improving confidence around the recognition and management of skin conditions for Aboriginal children.

Research

SNAP-Chat: the Staphylococcus aureus Network Adaptive Platform Trial (SNAP) - Chat

Dr Anita Asha Campbell Bowen MBBS, DCH, PG DipPID, FRACP, PhD BA MBBS DCH FRACP PhD GAICD FAHMS OAM Infectious Diseases Physician; Raine Clinician

Research

A Survey of Infectious Diseases and Microbiology Clinicians in Australia and New Zealand About the Management of Staphylococcus aureus Bacteremia

Significant variation in practice, particularly for patients with a severe disease phenotype and antibiotic-resistant profile

Research

Antimicrobial stewardship in remote primary healthcare across northern Australia

The high burden of infectious disease and associated antimicrobial use likely contribute to the emergence of antimicrobial resistance in remote Australian Aboriginal communities. We aimed to develop and apply context-specific tools to audit antimicrobial use in the remote primary healthcare setting.

Research

Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess

We conducted a systematic review of clinical trials and observational studies that address the utility of SXT for SSTI treatment, caused by either GAS or MRSA

Research

Clinical and Molecular Epidemiology of an Emerging Panton-Valentine Leukocidin-Positive ST5 Methicillin-Resistant Staphylococcus aureus Clone in Northern Australia

Recently, we identified a Staphylococcus aureus sequence type 5 (ST5) clone in northern Australia with discrepant trimethoprim-sulfamethoxazole (SXT) susceptibility results. We aimed to identify isolates of this clone using Vitek 2 SXT resistance as a proxy and to compare its epidemiology with those of other circulating S. aureus strains. We collated Vitek 2 susceptibility data for S. aureus isolates collected through our laboratory and conducted a prospective, case-control study comparing clinical, microbiological, epidemiological, and genomic data for subsets of isolates reported as SXT resistant (cases) and SXT susceptible (controls) by Vitek 2.

Research

Yarning with a remote Aboriginal community about the next steps for achieving healthy skin

Skin health is widely recognised as being important for overall good health and well-being, yet the burden of skin infections in remote Aboriginal communities remains high. This project aimed to explore if virtual support for skin health could be a strategy to reduce community barriers to skin health engagement. 

Research

Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.